PRIOR AUTHORIZATION CRITERIA

BRAND NAME*
(generic)

INVEGA TRINZA
(paliperidone palmitate extended-release injectable suspension)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization ***Ref # 1270-A***

** Drugs that are listed in the target drug box include both brand and generic and all dosage forms and strengths unless otherwise stated*

FDA-APPROVED INDICATIONS

Invega Trinza (paliperidone palmitate), a 3-month injection, is indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invega Sustenna (1-month paliperidone palmitate extended-release injectable suspension) for at least four months.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- Invega Trinza is being prescribed for the treatment of schizophrenia
  AND
- The patient has been adequately treated with Invega Sustenna for at least four months

RATIONALE

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Invega Trinza is indicated for the treatment of schizophrenia in patients after they have been adequately treated with Invega Sustenna (1-month paliperidone palmitate extended-release injectable suspension) for at least four months. While many patients prefer oral medication, patients with recurrent relapses related to partial or full non-adherence are candidates for a long-acting injectable antipsychotic medication, as are patients who prefer the injectable formulation.[4]

The American Psychiatric Association (APA) states, with the possible exception of clozapine for the management of treatment-resistant symptoms, there currently is no definitive evidence that one atypical antipsychotic agent will have superior efficacy compared with another agent in the class, although meaningful differences in response may be observed in individual patients. Patient response and tolerance to antipsychotic agents are variable, and patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile. The choice of an antipsychotic agent should be individualized, considering past response to therapy, adverse effect profile (including the patient's experience of subjective effects such as dysphoria), and the patient's preference for a specific drug, including route of administration.[3,4]

REFERENCES

1. Invega Trinza [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; March 2017.
2. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed September 2017.
3. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed September 2017.
4. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Available a: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf. Accessed September 2017.

Written by: UM Development (CT)
Date Written: 05/2015

CRITERIA FOR APPROVAL

1	Is Invega Trinza being prescribed for the treatment of schizophrenia?	Yes	No
2	Has the patient been adequately treated with Invega Sustenna for at least four months?	Yes	No

Mapping Instructions			
	Yes	**No**	**DENIAL REASONS – DO NOT USE FOR MEDICARE PART D**
1.	Go to 2	Deny	Your plan covers this drug when you have schizophrenia. Your use of this drug does not meet the requirement. This is based on the information we have.
2.	Approve, 36 months	Deny	Your plan covers this drug when you have been treated with Invega Sustenna for at least four months. Your use of this drug does not meet the requirement. This is based on the information we have.